SI3133080T1 - Novi citostatski 7-deazapurin nukleozidi - Google Patents

Novi citostatski 7-deazapurin nukleozidi

Info

Publication number
SI3133080T1
SI3133080T1 SI200931882T SI200931882T SI3133080T1 SI 3133080 T1 SI3133080 T1 SI 3133080T1 SI 200931882 T SI200931882 T SI 200931882T SI 200931882 T SI200931882 T SI 200931882T SI 3133080 T1 SI3133080 T1 SI 3133080T1
Authority
SI
Slovenia
Prior art keywords
deazapurine nucleosides
novel cytostatic
cytostatic
novel
deazapurine
Prior art date
Application number
SI200931882T
Other languages
English (en)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of SI3133080T1 publication Critical patent/SI3133080T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00032—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by data exchange
    • H02J7/00036—Charger exchanging data with battery
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00047—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries with provisions for charging different types of batteries
SI200931882T 2008-01-18 2009-01-15 Novi citostatski 7-deazapurin nukleozidi SI3133080T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
EP16174985.8A EP3133080B1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Publications (1)

Publication Number Publication Date
SI3133080T1 true SI3133080T1 (sl) 2018-12-31

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200931882T SI3133080T1 (sl) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurin nukleozidi
SI200931535A SI2231689T1 (sl) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200931535A SI2231689T1 (sl) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi

Country Status (18)

Country Link
US (1) US8093226B2 (sl)
EP (2) EP2231689B1 (sl)
JP (2) JP5485172B2 (sl)
CN (1) CN101977923B (sl)
AU (1) AU2009204568B2 (sl)
CA (1) CA2711384C (sl)
CY (2) CY1118104T1 (sl)
DK (2) DK2231689T3 (sl)
ES (2) ES2598503T3 (sl)
HR (2) HRP20161344T1 (sl)
HU (2) HUE041598T2 (sl)
LT (2) LT2231689T (sl)
NZ (1) NZ586610A (sl)
PL (2) PL3133080T3 (sl)
PT (2) PT2231689T (sl)
SI (2) SI3133080T1 (sl)
TR (1) TR201815961T4 (sl)
WO (1) WO2009089804A1 (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2474545T3 (pl) 2005-12-13 2017-04-28 Incyte Holdings Corporation Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CN102459300B (zh) * 2009-04-22 2014-12-10 捷克有机化学和生物化学研究院 用于治疗用途的新的7-脱氮嘌呤核苷
CA2761954C (en) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2010249380B2 (en) * 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR081315A1 (es) * 2010-03-10 2012-08-08 Incyte Corp Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
MX2016001639A (es) 2013-08-07 2016-10-07 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10414788B2 (en) 2016-06-29 2019-09-17 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
UA127925C2 (uk) 2018-03-30 2024-02-14 Інсайт Корпорейшн Лікування гнійного гідраденіту з використанням інгібіторів jak
JP2022527556A (ja) * 2019-04-05 2022-06-02 プレリュード・セラピューティクス・インコーポレイテッド プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤
KR20220012349A (ko) * 2019-06-18 2022-02-03 다이호야쿠힌고교 가부시키가이샤 피롤로피리미딘 골격을 갖는 신규한 인산에스테르 화합물 또는 그 약학적으로 허용 가능한 염
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (sl) * 1974-03-19 1975-10-01
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
CA2537114C (en) * 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
AU2005317081A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
SI2231689T1 (sl) 2016-11-30
HRP20181774T1 (hr) 2018-12-28
EP2231689B1 (en) 2016-07-20
JP2011509949A (ja) 2011-03-31
CY1118104T1 (el) 2017-06-28
EP3133080B1 (en) 2018-08-01
ES2693551T3 (es) 2018-12-12
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
DK2231689T3 (en) 2016-09-19
EP2231689A1 (en) 2010-09-29
ES2598503T3 (es) 2017-01-27
TR201815961T4 (tr) 2018-11-21
JP2014058567A (ja) 2014-04-03
DK3133080T3 (en) 2018-11-26
US8093226B2 (en) 2012-01-10
CN101977923B (zh) 2014-10-08
CA2711384C (en) 2016-07-26
CA2711384A1 (en) 2009-07-23
CN101977923A (zh) 2011-02-16
PL2231689T3 (pl) 2017-01-31
HUE030767T2 (en) 2017-05-29
PL3133080T3 (pl) 2018-12-31
AU2009204568A1 (en) 2009-07-23
LT2231689T (lt) 2016-10-25
CY1121364T1 (el) 2020-05-29
JP5485172B2 (ja) 2014-05-07
LT3133080T (lt) 2018-11-12
EP3133080A1 (en) 2017-02-22
PT2231689T (pt) 2016-10-07
HRP20161344T1 (hr) 2016-11-18
HUE041598T2 (hu) 2019-05-28
AU2009204568B2 (en) 2013-10-03
NZ586610A (en) 2012-08-31
US20090203637A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
HRP20181774T1 (hr) Novi citostatski 7-deazapurinski nukleosidi
HRP20171398T1 (hr) Novi derivati adenina
HK1209129A1 (en) Novel 7-deazapurine nucleosides for therapeutic uses 7-
ZA201008829B (en) Nucleoside cyclicphosphates
IL213698A0 (en) Nucleoside phosphoramidates
ZA201104638B (en) Nucleoside analogs
IL200831A0 (en) Novel adenine compounds
EP2138497A4 (en) NEW ADENINE CONNECTION
IL213701A0 (en) Synthesis of purine nucleosides
ZA201103943B (en) Purine compounds
ZA201003438B (en) Antiviral nucleoside compounds
IL210207A0 (en) Compounds having antiviral properties
GB0803707D0 (en) Antiviral agent
EP2209817A4 (en) ANTIVIRAL COMPOSITIONS
GB0723609D0 (en) Antiviral
ZA201005416B (en) Cytostatic composition
IL192335A0 (en) Antiviral compounds
GB0819528D0 (en) Antiviral compounds
GB0816600D0 (en) Antiviral compounds
GB0704852D0 (en) Furanose derivatives
GB0717955D0 (en) Preparation of modified nucleosides